The EACH/PIC Coalition submitted comments to the Nevada Assembly Ways and Means Committee opposing AB 259, which would cap reimbursement rates at the “maximum fair price” rates negotiated in the […]
The EACH/PIC Coalition submitted a comment letter to the CO PDAB for consideration during the rulemaking hearing to establish an upper payment limit for Enbrel. The letter states: “Proceeding with
The EACH/PIC Coalition submitted a comment letter to the OR PDAB on the subset list of drugs and insulin products selected by the Oregon board for further review and the
The EACH/PIC Coalition submitted a comment letter to the MD PDAB on their ongoing cost review process and input to inform the board’s review of Farxiga. The letter stated: “We
The EACH/PIC Coalition submitted comments to the Delaware Senate Health and Social Services Committee opposing provisions in SJR 7, which would cap reimbursement rates at the “maximum fair price” rates
The EACH/PIC Coalition submitted comments to the Rhode Island Senate Health and Human Services Committee opposing SB 468, which would cap reimbursement rates at the “maximum fair price” rates negotiated
The EACH/PIC Coalition submitted written testimony to the Michigan House Committee on Government Operations ahead of consideration of S.B. 3-5. The letter urged the committee to oppose the legislation that
The EACH/PIC Coalition submitted written testimony to the Michigan Senate Committee on Finance, Insurance, and Consumer Protection ahead of consideration of S.B. 3-5. The letter urged the committee to oppose
The EACH/PIC Coalition submitted a letter to Maryland Governor Wes Moore urging him to veto S.B. 357/H.B. 424, which would expand the upper payment limit (UPL) authority of the Maryland
The EACH/PIC Coalition submitted comments to the Oregon PDAB ahead of their April meeting, providing feedback on the current Request for Information (RFI) process, public engagement opportunities, and the overall
